Skip to main content

and
  1. Article

    Open Access

    Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

    Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung...

    Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama in BMC Cancer (2022)